S&P 500   4,379.50 (-1.43%)
DOW   34,509.92 (-1.03%)
QQQ   363.72 (-1.79%)
AAPL   144.08 (-0.89%)
MSFT   287.96 (-2.11%)
FB   343.80 (-2.77%)
GOOGL   2,750.70 (-2.51%)
TSLA   783.95 (-0.94%)
AMZN   3,339.15 (-1.96%)
NVDA   210.12 (-2.99%)
BABA   150.99 (+0.54%)
NIO   35.77 (-2.72%)
CGC   14.63 (-0.54%)
GE   105.44 (+0.09%)
MU   73.54 (-2.18%)
AMD   105.48 (-2.48%)
T   27.44 (+0.15%)
F   14.54 (+2.68%)
ACB   6.60 (+3.29%)
DIS   176.10 (-1.21%)
PFE   42.71 (-1.97%)
BA   221.81 (-1.05%)
AMC   37.87 (-3.64%)
S&P 500   4,379.50 (-1.43%)
DOW   34,509.92 (-1.03%)
QQQ   363.72 (-1.79%)
AAPL   144.08 (-0.89%)
MSFT   287.96 (-2.11%)
FB   343.80 (-2.77%)
GOOGL   2,750.70 (-2.51%)
TSLA   783.95 (-0.94%)
AMZN   3,339.15 (-1.96%)
NVDA   210.12 (-2.99%)
BABA   150.99 (+0.54%)
NIO   35.77 (-2.72%)
CGC   14.63 (-0.54%)
GE   105.44 (+0.09%)
MU   73.54 (-2.18%)
AMD   105.48 (-2.48%)
T   27.44 (+0.15%)
F   14.54 (+2.68%)
ACB   6.60 (+3.29%)
DIS   176.10 (-1.21%)
PFE   42.71 (-1.97%)
BA   221.81 (-1.05%)
AMC   37.87 (-3.64%)
S&P 500   4,379.50 (-1.43%)
DOW   34,509.92 (-1.03%)
QQQ   363.72 (-1.79%)
AAPL   144.08 (-0.89%)
MSFT   287.96 (-2.11%)
FB   343.80 (-2.77%)
GOOGL   2,750.70 (-2.51%)
TSLA   783.95 (-0.94%)
AMZN   3,339.15 (-1.96%)
NVDA   210.12 (-2.99%)
BABA   150.99 (+0.54%)
NIO   35.77 (-2.72%)
CGC   14.63 (-0.54%)
GE   105.44 (+0.09%)
MU   73.54 (-2.18%)
AMD   105.48 (-2.48%)
T   27.44 (+0.15%)
F   14.54 (+2.68%)
ACB   6.60 (+3.29%)
DIS   176.10 (-1.21%)
PFE   42.71 (-1.97%)
BA   221.81 (-1.05%)
AMC   37.87 (-3.64%)
S&P 500   4,379.50 (-1.43%)
DOW   34,509.92 (-1.03%)
QQQ   363.72 (-1.79%)
AAPL   144.08 (-0.89%)
MSFT   287.96 (-2.11%)
FB   343.80 (-2.77%)
GOOGL   2,750.70 (-2.51%)
TSLA   783.95 (-0.94%)
AMZN   3,339.15 (-1.96%)
NVDA   210.12 (-2.99%)
BABA   150.99 (+0.54%)
NIO   35.77 (-2.72%)
CGC   14.63 (-0.54%)
GE   105.44 (+0.09%)
MU   73.54 (-2.18%)
AMD   105.48 (-2.48%)
T   27.44 (+0.15%)
F   14.54 (+2.68%)
ACB   6.60 (+3.29%)
DIS   176.10 (-1.21%)
PFE   42.71 (-1.97%)
BA   221.81 (-1.05%)
AMC   37.87 (-3.64%)
NASDAQ:ADPT

Adaptive Biotechnologies Stock Forecast, Price & News

$34.44
-1.39 (-3.88 %)
(As of 09/28/2021 09:58 AM ET)
Add
Compare
Today's Range
$34.29
$35.74
50-Day Range
$30.02
$39.78
52-Week Range
$29.74
$71.25
Volume664 shs
Average Volume825,733 shs
Market Capitalization$4.85 billion
P/E RatioN/A
Dividend YieldN/A
Beta0.27
30 days | 90 days | 365 days | Advanced Chart
Receive ADPT News and Ratings via Email

Sign-up to receive the latest news and ratings for Adaptive Biotechnologies and its competitors with MarketBeat's FREE daily newsletter.


Adaptive Biotechnologies logo

About Adaptive Biotechnologies

Adaptive Biotechnologies Corp. engages in the development of an immune medicine platform. It harnesses the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its products and services include immunoSEQ, clonoSEQ, cellular therapy, and vaccines. The company was founded by Chad Robins, Harlan Robins, and Chris Carlson in September 2009 and is headquartered in Seattle, WA.

Headlines

See More Headlines

Industry, Sector and Symbol

Industry
Biological products, except diagnostic
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:ADPT
CIK
N/A
Employees
622
Year Founded
N/A

Sales & Book Value

Annual Sales
$98.38 million
Book Value
$5.43 per share

Profitability

Net Income
$-146,230,000.00
Net Margins
-128.33%

Debt

Price-To-Earnings

Miscellaneous

Market Cap
$4.85 billion
Next Earnings Date
11/9/2021 (Estimated)
Optionable
Not Optionable

MarketRank

Overall MarketRank

2.13 out of 5 stars

Medical Sector

431st out of 1,353 stocks

Biological Products, Except Diagnostic Industry

69th out of 195 stocks

Analyst Opinion: 3.3Community Rank: 4.3Dividend Strength: 0.0Insider Behavior: 2.5Valuation: 0.6 5 -4 -3 -2 -1 -












Adaptive Biotechnologies (NASDAQ:ADPT) Frequently Asked Questions

Is Adaptive Biotechnologies a buy right now?

4 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Adaptive Biotechnologies in the last twelve months. There are currently 2 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Adaptive Biotechnologies stock.
View analyst ratings for Adaptive Biotechnologies
or view top-rated stocks.

What stocks does MarketBeat like better than Adaptive Biotechnologies?

Wall Street analysts have given Adaptive Biotechnologies a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Adaptive Biotechnologies wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is Adaptive Biotechnologies' next earnings date?

Adaptive Biotechnologies is scheduled to release its next quarterly earnings announcement on Tuesday, November 9th 2021.
View our earnings forecast for Adaptive Biotechnologies
.

How were Adaptive Biotechnologies' earnings last quarter?

Adaptive Biotechnologies Co. (NASDAQ:ADPT) issued its quarterly earnings results on Tuesday, August, 3rd. The company reported ($0.35) EPS for the quarter, beating the consensus estimate of ($0.43) by $0.08. The firm earned $38.50 million during the quarter, compared to the consensus estimate of $31.12 million. Adaptive Biotechnologies had a negative trailing twelve-month return on equity of 23.32% and a negative net margin of 128.33%. The company's quarterly revenue was up 83.3% on a year-over-year basis. During the same period in the prior year, the business posted ($0.26) earnings per share.
View Adaptive Biotechnologies' earnings history
.

How has Adaptive Biotechnologies' stock been impacted by COVID-19 (Coronavirus)?

Adaptive Biotechnologies' stock was trading at $21.52 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, ADPT stock has increased by 66.5% and is now trading at $35.83.
View which stocks have been most impacted by COVID-19
.

What guidance has Adaptive Biotechnologies issued on next quarter's earnings?

Adaptive Biotechnologies issued an update on its FY 2021 earnings guidance on Wednesday, August, 25th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $148 million-$155 million, compared to the consensus revenue estimate of $150.16 million.

What price target have analysts set for ADPT?

4 Wall Street analysts have issued 12-month price objectives for Adaptive Biotechnologies' shares. Their forecasts range from $52.00 to $74.00. On average, they expect Adaptive Biotechnologies' share price to reach $60.25 in the next twelve months. This suggests a possible upside of 68.2% from the stock's current price.
View analysts' price targets for Adaptive Biotechnologies
or view top-rated stocks among Wall Street analysts.

Who are Adaptive Biotechnologies' key executives?

Adaptive Biotechnologies' management team includes the following people:

What is Chad Robins' approval rating as Adaptive Biotechnologies' CEO?

51 employees have rated Adaptive Biotechnologies CEO Chad Robins on Glassdoor.com. Chad Robins has an approval rating of 92% among Adaptive Biotechnologies' employees. This puts Chad Robins in the top 30% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Adaptive Biotechnologies own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Adaptive Biotechnologies investors own include NVIDIA (NVDA), Alibaba Group (BABA), QUALCOMM (QCOM), Johnson & Johnson (JNJ), Advanced Micro Devices (AMD), CrowdStrike (CRWD), The Home Depot (HD), Inovio Pharmaceuticals (INO), PayPal (PYPL) and Tesla (TSLA).

When did Adaptive Biotechnologies IPO?

(ADPT) raised $200 million in an initial public offering on Thursday, June 27th 2019. The company issued 12,500,000 shares at a price of $15.00-$17.00 per share. Goldman Sachs, J.P. Morgan and BofA Merrill Lynch served as the underwriters for the IPO and Cowen, Guggenheim Securities, William Blair and BTIG were co-managers.

What is Adaptive Biotechnologies' stock symbol?

Adaptive Biotechnologies trades on the NASDAQ under the ticker symbol "ADPT."

Who are Adaptive Biotechnologies' major shareholders?

Adaptive Biotechnologies' stock is owned by many different retail and institutional investors. Top institutional shareholders include Matrix Capital Management Company LP (8.38%), Price T Rowe Associates Inc. MD (7.79%), Vanguard Group Inc. (7.23%), BlackRock Inc. (3.78%), ARK Investment Management LLC (3.11%) and Neuberger Berman Group LLC (1.56%). Company insiders that own Adaptive Biotechnologies stock include Andris A Zoltners, Chad M Cohen, Chad M Cohen, Chad M Robins, Chad M Robins, Charles Sang, David E Goel, Egon Durban, Eric Dobmeier, Euclidean Capital Llc, Francis Lo, Global Investors Lp Viking, Harlan S Robins, Harlan S Robins, Julie Rubinstein, Jyoti Palaniappan, Lance Baldo, Michael J Pellini, Michelle Renee Griffin, Nancy Louise Hill, R Mark Adams, Robert Hershberg, Sharon Benzeno, Stacy L Taylor, Susan Bobulsky and Viking Global Performance Llc.
View institutional ownership trends for Adaptive Biotechnologies
.

Which major investors are selling Adaptive Biotechnologies stock?

ADPT stock was sold by a variety of institutional investors in the last quarter, including JPMorgan Chase & Co., Wells Fargo & Company MN, Rockefeller Capital Management L.P., Matrix Capital Management Company LP, FMR LLC, Chilton Investment Co. LLC, Frontier Capital Management Co. LLC, and UBS Asset Management Americas Inc.. Company insiders that have sold Adaptive Biotechnologies company stock in the last year include Chad M Cohen, Chad M Robins, Charles Sang, David E Goel, Egon Durban, Eric Dobmeier, Euclidean Capital Llc, Francis Lo, Global Investors Lp Viking, Harlan S Robins, Julie Rubinstein, Jyoti Palaniappan, Lance Baldo, Michael J Pellini, Michelle Renee Griffin, Nancy Louise Hill, R Mark Adams, Robert Hershberg, Sharon Benzeno, Stacy L Taylor, and Susan Bobulsky.
View insider buying and selling activity for Adaptive Biotechnologies
or view top insider-selling stocks.

Which major investors are buying Adaptive Biotechnologies stock?

ADPT stock was bought by a variety of institutional investors in the last quarter, including Sumitomo Mitsui Trust Holdings Inc., Nikko Asset Management Americas Inc., Price T Rowe Associates Inc. MD, Bellevue Group AG, ARK Investment Management LLC, State Street Corp, BlackRock Inc., and Allianz Asset Management GmbH.
View insider buying and selling activity for Adaptive Biotechnologies
or or view top insider-buying stocks.

How do I buy shares of Adaptive Biotechnologies?

Shares of ADPT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Adaptive Biotechnologies' stock price today?

One share of ADPT stock can currently be purchased for approximately $35.83.

How much money does Adaptive Biotechnologies make?

Adaptive Biotechnologies has a market capitalization of $5.04 billion and generates $98.38 million in revenue each year. The company earns $-146,230,000.00 in net income (profit) each year or ($1.11) on an earnings per share basis.

How many employees does Adaptive Biotechnologies have?

Adaptive Biotechnologies employs 622 workers across the globe.

What is Adaptive Biotechnologies' official website?

The official website for Adaptive Biotechnologies is www.constructionpartners.net.

Where are Adaptive Biotechnologies' headquarters?

Adaptive Biotechnologies is headquartered at 1551 EASTLAKE AVENUE EAST SUITE 200, SEATTLE WA, 98102.

How can I contact Adaptive Biotechnologies?

Adaptive Biotechnologies' mailing address is 1551 EASTLAKE AVENUE EAST SUITE 200, SEATTLE WA, 98102. The company can be reached via phone at (206) 659-0067 or via email at [email protected].


This page was last updated on 9/28/2021 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.